CCI
28
3
A
47
6
MPC
28
2
GS
52
-7
COF
57
-2
JNJ
42
-2
LRCX
43
-2
CINF
37
6
BSX
61
2
EXPE
74
2
HBI
50
-2
FOXA
59
7
CHRW
50
13
ROST
54
9
JWN
52
2
EMR
50
2
NAVI
43
16
IRM
65
2
COST
50
2
MDT
59
-3
CCI
28
3
A
47
6
MPC
28
2
GS
52
-7
COF
57
-2
JNJ
42
-2
LRCX
43
-2
CINF
37
6
BSX
61
2
EXPE
74
2
HBI
50
-2
FOXA
59
7
CHRW
50
13
ROST
54
9
JWN
52
2
EMR
50
2
NAVI
43
16
IRM
65
2
COST
50
2
MDT
59
-3
Financhill
Back

4D Molecular Therapeutics 10K Form

Sell
26

FDMT
4D Molecular Therapeutics

Last Price:
8.26
Seasonality Move:
106.87%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2021-03-25 10K FDMT/4D Molecular Therapeutics Annual

Receive FDMT News And Ratings

See the #1 stock for the next 7 days that we like better than FDMT

FDMT Financial Statistics

Sales & Book Value

Annual Sales: $20.72M
Cash Flow: $-30.59M
Price / Cash Flow: 0
Annual Sales: $11.33
Price / Book: 0.72

Profitability

EPS (TTM): -2.30000
Net Income (TTM): $-109.89M
Gross Margin: --
Return on Equity: -25.54%
Return on Assets: -23.85%

4D Molecular Therapeutics Earnings Forecast

Key 4D Molecular Therapeutics Financial Ratios

  • The Research & Development expenses have been 468.54% of Revenue.
  • The Net Earning history of FDMT is -486.59% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

4D Molecular Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: FDMT
CUSIP: 35104E
Website: 4dmoleculartherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 28.48
Quick Ratio: 27.93

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

FDMT Technical Analysis vs Fundamental Analysis

Sell
26
4D Molecular Therapeutics (FDMT) is a Sell

Is 4D Molecular Therapeutics a Buy or a Sell?